Jay Dave, DO
Neurology · Milford, DENPI 1215159488
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $125,087 of the $161,059 with a category attached, or 77.7%. 60 manufacturers reported payments, led by Biogen at 37.0% of the total. Reporting peaked in 2019 at $39,155 and has fallen 90.5% since, to $3,717 in 2025. Among neurology clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,055 payments — averaging $152.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$60K
- AbbVie$32K
- Biohaven Pharmaceuticals, Inc.$21K
- TG Therapeutics, Inc.$13K
- Sanofi$9K
- Biohaven Pharmaceutical Holding Company Ltd.$7K
- plus $18K from 54 others
What the payments were for
- Consulting fees$8,3995%
- Speaking & faculty fees$125,08778%
- Travel & lodging$5,3473%
- Food & beverage$22,12614%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$161,059 in reported general payments places this provider in the 95th percentile of 61 neurology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 20 | $225,247 |
| VumerityDiroximel Fumarate | 18 | $206,189 |
| Nurtec OdtRimegepant Sulfate | 102 | $171,458 |
| Aimovig AutoinjectorErenumab-Aooe | 107 | $137,922 |
| GilenyaFingolimod Hcl | 11 | $107,127 |
| Avonex (4 Pack)Interferon Beta-1a | 12 | $97,653 |
| UbrelvyUbrogepant | 63 | $89,171 |
| QuliptaAtogepant | 55 | $67,536 |
| AustedoDeutetrabenazine | 13 | $64,164 |
| VimpatLacosamide | 18 | $45,907 |
| Oxtellar XrOxcarbazepine | 19 | $41,478 |
| Emgality PenGalcanezumab-Gnlm | 24 | $33,569 |
| Memantine Hcl | 674 | $27,752 |
| RytaryCarbidopa/Levodopa | 12 | $25,250 |
| Rufinamide | 14 | $22,968 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenVumerity, Avonex (4 Pack) | $59,591 | $303,84130 claims |
| Grifols USA, LLCGamunex-C | $85 | $225,24720 claims |
| PfizerNurtec Odt | $521 | $171,458102 claims |
| AbbVieUbrelvy, Qulipta | $32,238 | $156,707118 claims |
| NovartisGilenya | $1,513 | $107,12711 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $760 | $64,16413 claims |
| UCB, Inc.Vimpat, Neupro | $272 | $55,49930 claims |
| Supernus Pharmaceuticals, Inc.Oxtellar Xr | $185 | $41,47819 claims |
| Amneal Pharmaceuticals LLCRytary, Mycophenolate Mofetil, Pyridostigmine Bromide | $360 | $36,726125 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $259 | $20,36315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 61 neurology providers in Delaware.
Other neurology in Milford
- Raid KofahiMilford$82
- Justin MartelloNewark$485K
- Abraham ScheerDover$231K
- Jason SilversteenNewark$202K
- Lawrence KempLewes$24K
- Etsegenet TizazuNewark$15K
- William SommersNewark$14K
- Lee DresserNewark$12K
- John PollardNewark$7K
- Shilpa KautaNewark$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.